Incyte (NASDAQ:INCY) EVP Sells $1,292,049.08 in Stock

Key Points

  • Incyte EVP Lee Heeson sold 10,694 shares for about $1.29 million, reducing his holdings by 28.46%; the transaction was made under a pre-arranged Rule 10b5-1 plan.
  • Incyte reported quarterly revenue of $1.56 billion, above the $1.46 billion consensus, and revenue rose 14% year over year; reported EPS of -$3.60 also beat estimates of -$3.93.
  • Analyst opinion is mixed: 11 analysts rate the stock Buy and 14 rate it Hold, for a consensus Hold rating and an average price target of $133.86.

Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Lee Heeson sold 10,694 shares of the company's stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $120.82, for a total transaction of $1,292,049.08. Following the completion of the sale, the executive vice president directly owned 26,884 shares of the company's stock, valued at $3,248,124.88. The trade was a 28.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Incyte Stock Down 1.0%

Shares of INCY opened at $119.09 on Wednesday. The firm has a market capitalization of $24.27 billion, a PE ratio of 63.35, a P/E/G ratio of 4.38 and a beta of 0.78. The firm has a 50-day moving average price of $118.94 and a 200 day moving average price of $109.14. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60.




Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the previous year, the firm earned $2.26 EPS. Incyte's revenue was up 14.0% on a year-over-year basis. On average, equities analysts expect that Incyte Corporation will post 2.24 EPS for the current year.

Analyst Upgrades and Downgrades

INCY has been the topic of several recent analyst reports. Canaccord Genuity Group assumed coverage on Incyte in a report on Thursday, August 20th. They set a "buy" rating and a $152.00 target price on the stock. Citigroup reaffirmed a "buy" rating on shares of Incyte in a research note on Monday, August 3rd. Stifel Nicolaus lifted their price target on Incyte from $145.00 to $157.00 and gave the company a "buy" rating in a research report on Monday, October 5th. Guggenheim lifted their price target on Incyte from $136.00 to $150.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Finally, BMO Capital Markets reissued a "market perform" rating on shares of Incyte in a research note on Tuesday, October 27th. Eleven research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $133.86.

View Our Latest Report on Incyte

Recent Incyte Headlines

Here are a few of the latest headlines about INCY:

  • Positive Sentiment: The European Commission approved Povofortay as the first once-daily oral treatment for moderate-to-severe HS in Europe. The decision gives Incyte a new commercial opportunity in a chronic skin condition and a differentiated oral option for patients. The approval could support future growth, although the news does not specify launch timing or expected sales. Company announcement
  • Neutral Sentiment: EVP Lee Heeson sold 10,694 shares for about $1.29 million, reducing his holdings by 28.46%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it less clearly a signal about the executive’s view of the company. Insider sale report

Hedge Funds Weigh In On Incyte

Several large investors have recently made changes to their positions in INCY. Global Retirement Partners LLC lifted its stake in shares of Incyte by 3.1% in the 3rd quarter. Global Retirement Partners LLC now owns 2,834 shares of the biopharmaceutical company's stock valued at $344,000 after purchasing an additional 84 shares during the period. EP Wealth Advisors LLC grew its stake in Incyte by 0.8% during the third quarter. EP Wealth Advisors LLC now owns 10,950 shares of the biopharmaceutical company's stock worth $1,329,000 after purchasing an additional 87 shares during the period. Hantz Financial Services Inc. grew its stake in Incyte by 6.8% during the third quarter. Hantz Financial Services Inc. now owns 1,446 shares of the biopharmaceutical company's stock worth $175,000 after purchasing an additional 92 shares during the period. Greenleaf Trust grew its stake in Incyte by 2.8% during the second quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company's stock worth $381,000 after purchasing an additional 93 shares during the period. Finally, Parallel Advisors LLC grew its stake in Incyte by 2.4% during the third quarter. Parallel Advisors LLC now owns 5,082 shares of the biopharmaceutical company's stock worth $617,000 after purchasing an additional 121 shares during the period. Institutional investors own 96.97% of the company's stock.

About Incyte

(Get Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Recommended Stories

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Incyte?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Incyte and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles